CN106562995A - Preparation method for preparing swan embryos and application of swan embryos - Google Patents
Preparation method for preparing swan embryos and application of swan embryos Download PDFInfo
- Publication number
- CN106562995A CN106562995A CN201610943264.XA CN201610943264A CN106562995A CN 106562995 A CN106562995 A CN 106562995A CN 201610943264 A CN201610943264 A CN 201610943264A CN 106562995 A CN106562995 A CN 106562995A
- Authority
- CN
- China
- Prior art keywords
- swan
- eggembryosin
- cell
- cells
- embryos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 210000002257 embryonic structure Anatomy 0.000 title abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 44
- 210000001161 mammalian embryo Anatomy 0.000 claims description 34
- 210000001519 tissue Anatomy 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 13
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- 241000272814 Anser sp. Species 0.000 claims description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 9
- 108010000912 Egg Proteins Proteins 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 230000012447 hatching Effects 0.000 claims description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 210000004681 ovum Anatomy 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 6
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 6
- 229940116977 epidermal growth factor Drugs 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 229960004747 ubidecarenone Drugs 0.000 claims description 5
- 208000017667 Chronic Disease Diseases 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229960000271 arbutin Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 230000033912 thigmotaxis Effects 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 210000000130 stem cell Anatomy 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 8
- 239000012535 impurity Substances 0.000 abstract description 4
- 210000001835 viscera Anatomy 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 241001494479 Pecora Species 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102400001368 Epidermal growth factor Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 4
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000005059 dormancy Effects 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000010297 mechanical methods and process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VPMBPDKLCXQCSR-UHFFFAOYSA-N sodium;1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound [Na].ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O VPMBPDKLCXQCSR-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- -1 dry Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002304 esc Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000024642 stem cell division Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100313164 Caenorhabditis elegans sea-1 gene Proteins 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000272780 Cygnus Species 0.000 description 1
- 241001641735 Cygnus cygnus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- NPOSZHMWEFFGNH-UHFFFAOYSA-N [N].OC(=O)C(Cl)(Cl)Cl Chemical compound [N].OC(=O)C(Cl)(Cl)Cl NPOSZHMWEFFGNH-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a preparation method for preparing swan embryos. The method comprises the steps of subjecting swan embryonic stem cells to cell membrane breaking treatment, removing impurities, and extracting to obtain the swan pluripotent embryos. The invention also discloses swan embryos prepared by the above method, and the application of swan embryos. According to the technical scheme of the invention, swan pluripotent embryos are separated from swan embryonic stem cells, and the effects of human embryos can be realized. That means, various cells in a human body are ensured to stay active, and the service lives of working cells are prolonged. Meanwhile, damaged cells are repaired and the functions of cells are recovered. Dormant cells in the human body are activated, and effective working cells are supplemented. Moreover, the attenuation of stem cells themselves is protected and the generation of stem cells is promoted. Dormant stem cells are activated to generate new cells for replacing dead cells. Therefore, the purpose of recovering the internal organs of the human body is realized.
Description
Technical field
The present invention relates to drug medication technical field, especially a kind of swan eggembryosin, specifically address the swan eggembryosin
Preparation method and application.
Background technology
Although human diseasess have thousands of kinds, but real disease only has one kind, that is, cytopathy, any one organ
Cell metabolism it is out of joint, cell death reaches to a certain degree, then this organ just can it is sick, cause cell failure
Main reasons is that in terms of two：One is cytotrophy, oxygen supply is not enough, and two is that metabolic waste can not be discharged in time and be caused cell
The reason for caused by poisoning, and the present understanding to disease is the performance of disease, rather than real, mostly controls in treatment to the ill
Treat (the such as process of pain, heating etc.) or to treatment-resistant (excision to tumor, Radiotherapy chemotherapy etc.), most diseases are all right
Disease is controlled.This research is to activate itself internal stem cell division using this group of biomolecule of swan eggembryosin and go out new functioning cell to replace
In generation, damages and dead cell, and recovers and normal function, reaches the purpose for fundamentally treating disease.
1912, Switzerland scientist karr professor has in finding sheep embryonic cell first a kind of can make what cell rejuvenated
Magical material -- sheep embryo extract；1931, the mode of Ni Han professor's first passage injections was by the parathyroid cells application of lamb
Yu Yiwei impaired patients In danger of parathyroid gland in operation have saved its life；Nineteen thirty-seven, professor Ni Han for the first time will be living thin
Born of the same parents' therapy is applied to brain nervous cell, after, living cells therapy is extended to liver, pancreas, kidney, the heart by professor Ni Han
Dirty, duodenum, thymus and spleen.As sheep embryo extract is from the embryonic cell of sheep, there are all many-sides not with human cell
Together, there are many contraindications, such as over anaphylaxis crowd during clinical practice, hyperthyroidism, serious hyperpietic are pregnant
Phase women's use, tumor patient etc. can not be applied.
As fresh and alive cell can not be preserved for a long time, the scientist of 1949 Nian Nihan professors and Nestle company assists jointly
Make, developing lyophilizing living cells first carries out cell activation treatment；Nineteen fifty-five Switzerland Dr.Alfred doctors of medicine Pfister portion
The defect of (lyophilizing is freezed) causes when point solving cell extraction damage and deteriorating course and Techniques of preserving.
Martin Evans in 1970 are isolated from mice blastular first and are gone out mouse embryo stem cell with In vitro culture
(embryonic stem cell, ESCs, abbreviation ES, EK or ESC cell.)；American scientist vitro culture of human embryo in 1998
Stem cell success, hereafter learns first scholar both at home and abroad using the different disease of different stem-cell therapies, and its short term therapy effect can
With affirmative, but presently, there are problems with：Either sheep placental extract or embryonic stem cell, due to being that xenogenesis (sheep) is all deposited with allosome
In immunological rejection, allergy, In vitro culture, polluted bacteria causes the severe complications such as systemic infection.
1980, as fresh and alive sheep embryo extract lacks the strict antibacterial measure of sterilization, it is impossible to long-term to preserve, there is infection
Dangerous very big, Switzerland's medical circle is devoted to development purification, sterilization, sterilization, Techniques of preserving always, but still can not reach long-time
The purpose of preservation.
Nineteen eighty-three, Edward doctor Bei Chi inherit the achievement of Buddhist nun's writing brush sheep embryo extract active therapy, develop personalization
Treatment technology, purifies " the full organ essence " for small molecule, more easily absorbs；Help human body activation and newly to bear structure complete
It is whole, the active neoblast of function；Replace due to aging sick cell caused by various cause noxa element institutes, strengthen each biosystem
Function, recovers human body energy and muscle power, reaches more significantly defying age curative effect.
2006, Chen Zhengyue, Huang Lijun, Xu Jianwen extracted the preparation side of eggembryosin from after hatching 10～13 days in Embryo Gallus domesticus
Method.There is to blood deficiency mice preferable promoting erythrocyte hemopoietic function using chick embryo element gavage, while cyclophosphamide is caused
Immune organ Quality Down has obvious effect of gain, while prove that chick embryo element has defying age and immunoregulation effect,
But follow-up relevant report is few, the report without clinical treatment patient.
The content of the invention
The present invention is directed to the deficiencies in the prior art, proposes a kind of swan eggembryosin preparation method and application, and proves swan
Eggembryosin can repair the stem cell division of resting state in the cell of body injury and activation body, produce new cell replacement dead
The cell died, and its effect is played, the effect of fundamentally disease preventing and treating is reached, and it is easy to operate, effect is extensive, so as to solve
This technical barrier.
Swan refers to swan race (scientific name：Cygnus, English name：Swan birds), have 8 kinds, belong to natatorial bird.Swan is large-scale
Birds, 1.5 meters maximum of height, more than 6,000 grams of body weight.Whooper swan is called white swan, swan, is a kind of large-scale natatorial bird, and body is about
1.5 meters, body weight can be more than 10 kilograms.Swan body is strong, 20 years or so life-span, elder up to more than 35 years, sexual maturity 3～4 years, this
It is long when in birds.Swan has abundant nutrition and medical value.
In order to realize foregoing invention purpose, the present invention provides technical scheme below：
A kind of preparation method of swan eggembryosin, comprises the steps：
(1) the extraction swan embryonic stem cell from swan embryo；
(2) cell rupture of membranes process is carried out to swan embryonic stem cell, successively including cell breakage process, centrifugal treating, is obtained
To swan eggembryosin；
Wherein, swan embryo takes from the hatching swan ovum of 10 days；
Gained embryonic stem cell is all-round and pluripotent stem cell, and gained swan eggembryosin is swan pluripotent embryonic element.
Preferably, in the step (2), the cell breakage is processed as 3 times of days are added in swan embryonic stem cell
The sterile pure water of goose embryonic stem cell volume, using ultrasound wave by cell breakage；
The centrifugal treating is the 3000r/min under 5 DEG C -50 DEG C of temperature conditionss, and 10-15 minutes are centrifuged.
Preferably, in the step (1), the swan embryonic stem cell is using trypsin or collagen protein ferment treatment
Goose embryonal tissue is isolated.
Preferably, the preparation method also includes the sterilization treatment to swan eggembryosin, continues 10 hours at a temperature of 60 DEG C.
The present invention also provides a kind of swan eggembryosin, is obtained using above-mentioned preparation method.
Preferably, the swan eggembryosin includes 42% Ubidecarenone, 6% aminoacid, 5% epidermal growth factor,
41% Arbutin, nucleic acid, pantothenic acid, immunoglobulin, Herba Bacopae monnieri, epidermis reparative factor and superoxide dismutase, it is described
The purity of swan eggembryosin is more than 98%.
The present invention also provides a kind of purposes of the swan eggembryosin by obtained in said method, for preparing treatment heart and brain blood
The medicine of these chronic diseases of pipe, diabetes, malignant tumor, gastroduodenal ulcer, hepatitis and defying age.
Preferably, the swan eggembryosin accounts for the 20%-30% of unit dose drug, the swan embryo in medicine is prepared
Tire element is omnipotent eggembryosin or orientation eggembryosin or the mixing of the two.
Preferably, consumption is：Swan eggembryosin concentration is 20% liquid preparation, takes in omnipotent eggembryosin 0.5ml every time,
Or orientation eggembryosin 1ml, every 1-2 days 1 time, continuous treatment 10-60 time.
Preferably, the medicine passes through subcutaneous injection, intradermal injection, intramuscular injection, the injection of disease portion, intravenous injection, tremulous pulse
The mode of injection, intrathecal injection, interventional therapy, stereotaxises, the sprinkling of focus surface or partial closure is administered.
Compared with prior art, the present invention has advantages below：At present without the infrastest of swan eggembryosin and clinical trial
Report, the manufacturing technology patent of invention without swan eggembryosin.Present invention swan multipotency isolated from swan embryonic stem cell
Eggembryosin and single energy eggembryosin mixture, the preparation method that the present invention is provided, using swan egg hatching, hatch the ratio of embryo
It is high；In hatching the 10th day, swan embryo weighed 2.31 grams；Therefore, preparation method of the invention goes out embryo and leads height；Embryonic stem cell
Yield is high；The potency of eggembryosin is high.Internal various cells can be made one to maintain vigour, extend the life-span of working cell；Repair and damage
Cell, recovers the function of cell；Activate internal rest cell, the effective working cell of supplement；The decay of protection autologous stem cells
Generate with promotion stem cell；Activate itself dormancy stem cell and differentiate the dead cell of new cell substitute, reach recovery internal organs
Effect, it both more than the therapeutical effect of current stem cell transplantation, and without the complication being likely to occur after stem cell transplantation, such as exempted from
Epidemic disease rejection, anaphylaxiss, infection etc., are fundamentally to treat all kinds of, various diseases, especially chronic, difficult disease,
Defying age, prolongation life-span, beauty etc..
Specific embodiment
Describe the present invention with reference to embodiment, the description of this part be only it is exemplary and explanatory, no
Reply protection scope of the present invention has any restriction effect.
The present invention is the day by extracting from swan embryonic stem cell (swan embryonic stem cell, SES)
Goose eggembryosin (SEF), is currently viewed as all kinds of incurable disease diseases for treatment, especially all kinds of chronic, difficult diseases
And defying age.
The action principle of SEF：The alternative Human embryo elements of SEF, can keep cell viability, extend the life-span of working cell；Repair
Multiple damaging cells, recover the function of cell；Extend the life-span of internal stem cell；Activate internal rest cell, the effective work of supplement
Make cell；Itself dormancy stem cell is activated, breaks up different tissues cell, to substitute the cell for updating aging, damage and death, made
Histoorgan restores, and reaches source radical curing of disease, reverses the effect in youth.
Swan is manually to put wild swan in recent years in a suitable place to breed, although is not easy to obtain, but is easy to hatching, and can obtain compared with high yield
The swan embryonic stem cell of amount.
Swan embryonic stem cell, from the swan incubating oosperm swan embryo of 10 days, obtains day using cell separation technology
Goose embryonic stem cell.After obtaining swan embryonal tissue, Eradicates removes all kinds of risk factor and impurity, using trypsin or collagen egg
White ferment treatment makes swan embryonal tissue decomposite embryonic cell.
Rupture of membranes process, including cell membrane and nucleus mould are carried out using physics and chemical method to swan embryonic stem cell, together
When can make antibacterial rupture of membranes, and deactivation.
Swan eggembryosin of the present invention is pluripotent embryonic element.
Swan eggembryosin (swan embryo factors, SEF) of the present invention, due to taking 10 Tian Nei swans embryonal tissues, its
The overwhelming majority is omnipotent embryo and pluripotent embryonic cell, so the eggembryosin for obtaining is omnipotent and pluripotent embryonic element, its work
With cell viability can be kept, extend the life-span of working cell；Damaging cells are repaired, recovers the function of cell；Activate internal dormancy
Cell, the effective working cell of supplement；The decay of protection autologous stem cells and promotion stem cell generate；Activate itself dormancy dry thin
Born of the same parents differentiate various types of cells, dead cell of substituting, and reach the effect for restoring internal organs, for treating various diseases, especially slowly
Property or difficult disease are very effective with defying age curative effect, the product can be preserved for a long time, avirulence, without rejection.
Embodiment 1
The present embodiment provides a kind of manufacture method of swan eggembryosin, comprises the following steps that：
1. swan embryonal tissue is obtained
1.1 selected germ cell：
The requirement of swan germ cell：Be preferred from Shandong manually put in a suitable place to breed wild swan, the disease-free, feeding and management of health it is correct,
The appropriate kind day gaggle of mating proportion, as the prescription of hatching egg, it is ensured that higher fertility rate and hatchability.According to yield
Require different, swan embryo quantity is different, can with 10,50 and 100 as a radix, the present invention according to test and experimental measuring with
100 swan embryos are a radix.
1.2 correct hatchings：
Swan ovum surface decontamination, swan ovum insert conventional incubation 10 days in incubator, take out swan embryo.
1.3 aseptic taking-up swan embryos：
After the clear water surface decontamination of swan ovum surface, leaching in strong element disinfectant solution (TCCA (Trichloroisocyanuric acid) sodium piece prepares liquid) is inserted
Bubble 10 minutes, the disinfectant solution are prepared by TCCA (Trichloroisocyanuric acid) sodium piece, every TCCA (Trichloroisocyanuric acid) sodium piece 250mg containing working substance,
It is equipped with by 50～100mg/L；Sterilization towel, then swan ovum is soaked 5 minutes in 75% ethanol, dry, shell, take out day
Goose embryo, Ovum Gallus domesticus album (Placenta Hominiss containing swan) and yolk are collected respectively, are placed in -18 DEG C of stored frozen, to treat that he uses, collect swan embryo, entirely
Journey sterile working.By using TCCA (Trichloroisocyanuric acid) sodium, alcohol disinfecting and whole sterile working, making sterilization more in the present embodiment
Strictly, bacteria-eliminating efficacy is more preferably.
The collection of 1.4 swan embryos：
Swan embryo achieved above is collected one and is being risen, swan embryo total amount about 231g or so.The day of normal growth to the 10th day
Goose embryo, embryo weigh about 2.31 grams, and the present embodiment gathers 100, i.e. 2.31x100=231g.
1.5 cleaning swan embryonal tissues：
Cell 15min is soaked using sterile pure water, Eradicates removes all kinds of risk factor, such as impurity, Ovum Gallus domesticus album, Placenta Hominiss, clot etc., instead
After rinsing swan embryonal tissue again, insert in sterile bag.The present embodiment soaks cell, the sterile pure water category by sterile pure water
Hypotonic medium, after frost cellularity can substantially changed, high, pure eggembryosin can be obtained.
The freezing of 1.5 swan embryos：
The swan embryonal tissue of packaging is placed in into -18 DEG C of freezings, daily room temperature naturalization ice 1 time, for three days on end.Be conducive to
Cellularity changes, and can obtain high yield eggembryosin.
2. stem cell is obtained from swan embryonal tissue
Extract omnipotent doing with many energy process below fine work in 2.1 swan embryonal tissues.
2.1.1 the defrosting of swan embryonal tissue：
Take out the swan embryonal tissue of freezing, naturally to thaw.
2.1.2 omnipotent and pluripotent stem cell is extracted from swan embryonal tissue：
Swan embryonal tissue is cut into small pieces, is divided during trypsin or collagen protein ferment treatment tissue never is respectively adopted
Cell is solved, is cell mixing, including major part is omnipotent, pluripotent stem cell, small part is unipotent stem cell and its hetero-organization
Cell, treats that next step is processed.
2.1.3 the identification of swan stem cell：
This research Bian alkali phosphatases (alkalinephosphatase, AKP), SEA-1, SEA-4, TRA-1-60, together
When also to be made karyotyping cultured cells to determine caryogram it is normal, and carry out internal, external Analytical Chemical Experiment.
3. eggembryosin is extracted from swan embryonic stem cell.
3.1 smudge cellses：
Various kinds of cell breaking method is had been developed at present, it is broken to adapt to different purposes and different types of cell wall.
Breaking method can be summarized as two big class of Mechanical Method and on-mechanical method.1. Mechanical Method：Including high-pressure homogenization crush method
(homogenization), vibrate pearl and hit crush method (Skaking Bead), high-speed stirred pearl grinding crush method (fine
Grinding), ultrasonic fragmentation (ultrasonication) etc..2. on-mechanical method：Osmotic shock crush method (osmotic
Shock), freeze thawing crush method (freezing and thawing), the molten crush method of enzyme (enzyme lysis), chemically fragmenting method
(chemical treatment) and detergent crush method (detergents) etc., according to environmental condition, are selected respectively.The present invention
Swan embryonal tissue and cell are added into the sterile pure water (hypotonic fluid) of 3 times of swan embryo's volumes, using supersonic cell
Pulverizer by cell breakage, in suspension liquid.
3.2SES Cell sap degreasings：
Fat in cell solution is removed using freezing method.
3.3 extract eggembryosin from SES Cell saps：
Using centrifuge at≤50 DEG C, and under >=5 DEG C of temperature conditionss, 3000r/min or so be centrifuged 15 minutes, by liquid with
Precipitate is separated, and is removed precipitate, is left and taken suspension.Both other impurities can remove and polypeptide structure had not been destroyed, and can have been obtained
More eggembryosins, operation are also more convenient.Between 5 DEG C -50 DEG C, the eggembryosin that both can have made extraction is in setting centrifuge temperature
Liquid, and have larger limit as temperature, it is ensured that the eggembryosin of extraction will not be inactivated, and preferably set centrifuge temperature at 5 DEG C -30
DEG C, further preferred 5 DEG C -10 DEG C, in the present embodiment, adopt 5 DEG C.
3.4 suspensions are filtered：
Suspension is crossed into ultrafiltration post of the molecular cut off more than 800000 dalton, ultrafiltrate, as swan embryo is obtained
Ultrafiltrate lyophilization is no longer obtained solid eggembryosin by plain solution, directly aseptic subpackaged preservation.It is to be detected.The present embodiment is adopted
With suspension preserve, advantage is the activity that can have both kept eggembryosin, again can the holding time it is long, be more beneficial for follow-up sterilizing.
4. the detection of swan eggembryosin.
The detection of 4.1 optical microscopes：
Using optics or electron microscope observation, free from admixture, it is acellular, see that little particle mixing liquid is the present embodiment and carries
Take the swan eggembryosin of preparation.
The detection of 4.2 biochemistry：
1. the measure of protein content：Spectrophotometer measurement method is adopted by kjeldahl nitrogen method, the content of protein is detected；②
The identification of molecular weight：Peptide content detection method is carried out using trichloroacetic acid nitrogen solubility index (THA-NSI) to enter suspension content
Row detection, molecular weight, below 180～1000 dalton, are that the material of small peptide, oligopeptide and polypeptide is eggembryosin.Jing biochemical analysises
Eggembryosin main component Ubidecarenone, aminoacid, EGF (epidermal growth factor), Arbutin, nucleic acid, pantothenic acid, immunoglobulin are false
Herba Portulacae, ERF (epidermis reparative factor), SOD (superoxide dismutase) etc., other compositions further need to be studied.3. purity is reflected
It is fixed：Identified using zone electrophoresiss method, clinical biochemical technology is shown in concrete operations；4. immunological identification：Using two-way agar diffusion
Test.
4.3 main component：
The detection of the swan eggembryosin Jing biological activity for extracting, draw eggembryosin that the inventive method extracts mainly into
Dividing includes：Ubidecarenone accounts for 42%；Aminoacid accounts for 6%, EGF (epidermal growth factor) and accounts for 5%；Arbutin, nucleic acid, pantothenic acid, immunity
Globulin, Herba Bacopae monnieri, ERF (epidermis reparative factor), SOD (superoxide dismutase) 41%, other 6%, its composition need to enter
One step research.The extraction ratio of this extracting method is more than 40%, i.e., the extractable animal embryo element per 1000g animal embryos tissue
More than 400g, and Purity result is more than 98%.
4.4 composition characteristic：
Ubidecarenone：It is a kind of vitamin, is also a kind of fat-soluble quinone, high-efficiency antioxidant agent can prevents arrhythmia, mistake
Quick disease, angina pectoriss, edema, hypertension and elimination superabundant fats.It plays very important effect in terms of slow down aging.Coenzyme
Q10 and vitamin C, E are much like, have helped neutralization.
Pantothenic acid：Vitamin 5 known to us, can potentially control worry, disappointment, anxiety, headache, confirmed fatigue etc., also
The sexual dysfunction that ethanol or Nicotiana tabacum L. cause can be helped improve.
Herba Bacopae monnieri：Research shows that Herba Bacopae monnieri can support the learning and memory part of brain.Herba Bacopae monnieri has antioxidation
Property, the region for determining memory can be protected and brain pressure is reduced.Tradition application is it has been shown that Herba Bacopae monnieri is to promoting brain function to have
Direct effect, such as strengthens focusing on and improving memory.
The sterilization treatment of 5.SEF
5.1 pass through cell rupture of membranes method
During rupture of membranes antibacterial also rupture of membranes and inactivate.
5.2 Baths spy's sterilization treatment (sterilizing and the poison that goes out)：
60 DEG C, continuous 10h.Thoroughly sterilizing is reached, the activity of eggembryosin can be kept again.Generally needed using high-temperature sterilization short
When sterilize, less than 6 hours.The present embodiment is carried out disinfection using continuous long-time higher temperature, fully and completely removes disease
Poison, while guarantee the biological activity of eggembryosin, it is visible in follow-up clinical test to have given play to efficient biological activity.
The safety examination of 6.SEF
6.1 carry out animal acute toxicity test, animal sensitivity test, rabbit pyrogenic test.
6.2 HIV (human immunodeficiency virus), second, hepatitis C virus detection.
6.3 antibacterial culturing are checked.
7.SEF concentration is prepared
Eggembryosin is configured to into 20% concentration with normal saline.
8. pack
It is bottled using bag flexible package or sealing.
The storage method of 9.SEF
1) place in -18 DEG C～5 DEG C refrigerators and can deposit 20 years.
2) under room temperature, i.e., less than 38 DEG C, 60 days can be preserved.
Embodiment 2
SEF treats zoopery
The model of different wounds and different 15 kinds of diseases is made from big white mice, rabbit, dog, monkey, is done with SEF using control
More than the 500 different zooperies of pre- sequential treatment, model include the representative disease of 15 kinds of following system：1st, dog head trauma
Wound model；2nd, monkey brain ischemia model；3rd, big white mice tumor model；4th, dog Chronic obstructive pulmonary disease；5th, dog stomach, 12
Duodenalulcer model；6th, dog hepatitis interstitialis chronica (liver cirrhosis) model；7th, dog hypertension model；8th, dog acute myocardial infarction ejector half；9、
Dog diabetes model；10th, dog extremity fracture model；11st, dog aplastic anemia model；12nd, dog Renal Failure Model；
13rd, dog condyloma acuminatum model；14th, rabbit arterial hardening obliteranses model；15th, big white mice defying age model.15 kinds of each system
Representative curative effect of disease is shown in Table 1.
1 SEF of table intervenes and compares (X ± S) with 15 kinds of curative effect of disease of conventional therapy
With to group than * P<0.01
Embodiment 3
The clinical practice test of SEF
The disease of 1.SEF treatments：
Embryo's extract for treating is adapted to each systemic disease, including subhealth state, promotion Children Normal growth, development, immune system
Defective disease, infection disease, tumor (all kinds of innocent and malignant tumours), nervous system disease, respiratory system disease, digestive system disease
Disease, cardiovascular system diseases, endocrine system disease, skeleton and musculature disease, disease in the blood system, urinary system disease
Disease, reproductive system disease, sexual function disease, peripheral blood vessel, skin disease, eye, ear, nose, pharynx, larynx difficult disease are anti-ageing
Old and beauty etc..
The disease number of cases of 2.SEF treatments：
More than 2000 example of Therapeutic Method sequential treatment patient of various diseases and defying age.
The therapeutic scheme of 3.SEF：
1. the selection of SEF：According to different diseases and the order of severity different eggembryosins of selection, omnipotent eggembryosin, multipotency embryo
Tire element and single energy eggembryosin.Omnipotent eggembryosin therapy (applying omnipotent eggembryosin) adapts to systemic disease, defying age；Pluripotent embryonic
Element is adapted to systemic disease；Single energy eggembryosin is adapted to certain disease (corresponding system).
2. course for the treatment of scheme：Low doses 10 times；The middle course for the treatment of 30 times；The long-range course for the treatment of 60 times.
3. course for the treatment of scheme：Low doses are applied to defying age；The middle course for the treatment of is applied to defying age+chronic disease；Long-term therapy is suitable for
In chronic disease or malignant tumor.
The Therapeutic Method of 4.SEF：
During compounding pharmaceutical, the swan eggembryosin accounts for the 20%-30% of unit dose drug, the day in medicine is prepared
Goose eggembryosin is omnipotent eggembryosin or orientation eggembryosin or the mixing of the two.
The liquid preparation that swan eggembryosin concentration is 20%-30% is formulated as in the present embodiment.Preferred concentration is 20%.Control
During treatment, the single dose for taking in omnipotent eggembryosin medicament is 0.5ml；The single dose of intake orientation eggembryosin medicament is 1ml.
In the present embodiment, indication Low doses are：Intake swan eggembryosin medicament 0.5ml, intramuscular injection, 1 times/day, continuous 10
It is secondary；In indication, the course for the treatment of is：Intake swan eggembryosin medicament 0.5ml, intramuscular injection, 1 time/next day, continuous 30 times；Indication long-term therapy
For：Intake swan eggembryosin medicament 0.5ml, intramuscular injection, 1 time/next day, it is annual continuous 60 times, continuous 3 years.
The therapeutic effect of 5.SEF：
More than 2000 example patient statistical results are treated all effectively according to this technology, responding time sees below list.
Patient's transformation period table after embryo's extract for treating
60 years old the elderly of defying age and beauty can be young 10 years old or so, extends life estimation and averagely can reach more than 40 years old
(the concrete observation that how much also takes time).
Different more than 200 example of various diseases of each system of sequential treatment of the present invention, main 16 kinds of each system code disease are faced
Bed Ureteral Calculus the results are shown in Table 2.
2 SEF of table intervenes and 16 kinds of disease patient's comparitive studies (X ± S) of conventional therapy
Other diseases more than 500, effective percentage is more than 98%.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of preparation method of swan eggembryosin, it is characterised in that comprise the steps：
(1) the extraction swan embryonic stem cell from swan embryo；
(2) cell rupture of membranes process is carried out to swan embryonic stem cell, successively including cell breakage process, centrifugal treating, day is obtained
Goose eggembryosin；
Wherein, swan embryo takes from the hatching swan ovum of 10 days；
Gained embryonic stem cell is all-round and pluripotent stem cell, and gained swan eggembryosin is swan pluripotent embryonic element.
2. the preparation method of swan eggembryosin as claimed in claim 1, it is characterised in that in step (2), at the cell breakage
Reason is the sterile pure water that 3 times of swan embryonic stem cell volumes are added in swan embryonic stem cell, using ultrasound wave by cell
It is broken；
The centrifugal treating is the 3000r/min under 5 DEG C -50 DEG C of temperature conditionss, and 10-15 minutes are centrifuged.
3. the preparation method of swan eggembryosin as claimed in claim 1, it is characterised in that in step (1), the swan embryo are done
Cell is isolated using trypsin or collagen protein ferment treatment goose embryonal tissue.
4. the preparation method of swan eggembryosin as claimed in claim 1, it is characterised in that also include the sterilizing to swan eggembryosin
Process, at a temperature of 60 DEG C, continue 10 hours.
5. a kind of swan eggembryosin, it is characterised in that obtained using the preparation method as described in claim 1-4 is arbitrary.
6. swan eggembryosin as claimed in claim 5, it is characterised in that including 42% Ubidecarenone, 6% aminoacid,
5% epidermal growth factor, 41% Arbutin, nucleic acid, pantothenic acid, immunoglobulin, Herba Bacopae monnieri, epidermis reparative factor and super
Superoxide dismutase, the purity of the swan eggembryosin is more than 98%.
7. a kind of purposes of swan eggembryosin as claimed in claim 6, it is characterised in that for preparing treatment cardiovascular and cerebrovascular vessel, sugar
The medicine of urine disease, malignant tumor, gastroduodenal ulcer, these chronic diseases of hepatitis and defying age.
8. the purposes of swan eggembryosin as claimed in claim 7, it is characterised in that the swan eggembryosin is accounted in medicine is prepared
The 20%-30% of unit dose drug, the swan eggembryosin are omnipotent eggembryosin or orientation eggembryosin or the mixing of the two.
9. the purposes of swan eggembryosin as claimed in claim 8, it is characterised in that consumption is：Swan eggembryosin concentration is
20% liquid preparation, takes in omnipotent eggembryosin 0.5ml, or orientation eggembryosin 1ml every time, every 1-2 days 1 time, continuous to treat
10-60 time.
10. as described in claim 7-9 is arbitrary swan eggembryosin purposes, it is characterised in that the medicine by subcutaneous injection,
Intradermal injection, intramuscular injection, the injection of disease portion, intravenous injection, intra-arterial injection, intrathecal injection, interventional therapy, stereotaxises, focus
Surface is sprayed or the mode of partial closure is administered.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610943264.XA CN106562995A (en) | 2016-10-26 | 2016-10-26 | Preparation method for preparing swan embryos and application of swan embryos |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610943264.XA CN106562995A (en) | 2016-10-26 | 2016-10-26 | Preparation method for preparing swan embryos and application of swan embryos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106562995A true CN106562995A (en) | 2017-04-19 |
Family
ID=58534803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610943264.XA Pending CN106562995A (en) | 2016-10-26 | 2016-10-26 | Preparation method for preparing swan embryos and application of swan embryos |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106562995A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491652A (en) * | 2016-10-26 | 2017-03-15 | 谢培增 | Goose eggembryosin preparation method and application |
| CN106511387A (en) * | 2016-10-26 | 2017-03-22 | 谢培增 | Preparing method and application of chicken embryo extracts |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101712947A (en) * | 2009-11-12 | 2010-05-26 | 浙江大学 | Preparation method and application of mesenchymal stem cells deriving from embryonic stem cells |
| CN102524839A (en) * | 2010-12-31 | 2012-07-04 | 黄佰钦 | Processing method of soft-shelled turtle embryo extract and finished product |
| CN102908365A (en) * | 2011-08-02 | 2013-02-06 | 天津泽世德生物医药有限公司 | Preparation method of eggembryosin |
| CN103462864A (en) * | 2013-06-10 | 2013-12-25 | 周斌 | Embryo water extract extracted from animal embryo internal organs, and extraction method and applications thereof |
| CN104814980A (en) * | 2015-04-03 | 2015-08-05 | 谢培增 | Production method and applications of human embryo fibroblasts |
| CN105497070A (en) * | 2015-12-28 | 2016-04-20 | 山东润泽制药有限公司 | Preparation method and application of sheep embryo living cell freeze-drying preparation |
-
2016
- 2016-10-26 CN CN201610943264.XA patent/CN106562995A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101712947A (en) * | 2009-11-12 | 2010-05-26 | 浙江大学 | Preparation method and application of mesenchymal stem cells deriving from embryonic stem cells |
| CN102524839A (en) * | 2010-12-31 | 2012-07-04 | 黄佰钦 | Processing method of soft-shelled turtle embryo extract and finished product |
| CN102908365A (en) * | 2011-08-02 | 2013-02-06 | 天津泽世德生物医药有限公司 | Preparation method of eggembryosin |
| CN103462864A (en) * | 2013-06-10 | 2013-12-25 | 周斌 | Embryo water extract extracted from animal embryo internal organs, and extraction method and applications thereof |
| CN104814980A (en) * | 2015-04-03 | 2015-08-05 | 谢培增 | Production method and applications of human embryo fibroblasts |
| CN105497070A (en) * | 2015-12-28 | 2016-04-20 | 山东润泽制药有限公司 | Preparation method and application of sheep embryo living cell freeze-drying preparation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491652A (en) * | 2016-10-26 | 2017-03-15 | 谢培增 | Goose eggembryosin preparation method and application |
| CN106511387A (en) * | 2016-10-26 | 2017-03-22 | 谢培增 | Preparing method and application of chicken embryo extracts |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106511387A (en) | Preparing method and application of chicken embryo extracts | |
| CN106109496B (en) | Human umbilical cord mesenchymal stem cells extract freeze-drying powder and preparation method | |
| CN104814980A (en) | Production method and applications of human embryo fibroblasts | |
| US11884953B2 (en) | Method for preparing protein peptide based on connective tissue and prepared protein peptide and use thereof | |
| JP2017190336A (en) | Acellular and bioabsorbable tissue regeneration matrix created by incubating acellular blood product | |
| CN103784474A (en) | Human fat mesenchymal stem cell extract and lyophilized powder and application thereof | |
| CN110157666A (en) | Umbilical cord mesenchymal stem cells MSCs and its cultural method and application | |
| EP3880217B1 (en) | Methods for preparing platelet releasate | |
| CN103596577A (en) | Pharmaceutical composition and topical use thereof | |
| CN106913583A (en) | The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents | |
| CN110448572A (en) | A kind of preparation method of umbilical cord mesenchymal stem cells active matter and the compound of cord blood stem cell active matter | |
| CN108486047A (en) | A kind of medical dressing and preparation method thereof of stem cell extract | |
| CN107384858A (en) | A kind of preparation method and applications of hypoxic tolerance type mescenchymal stem cell | |
| CN100564518C (en) | Placenta amnion cell extract and induce application in the differentiation at mescenchymal stem cell | |
| US3676551A (en) | Process for obtaining extracts from animal tissues | |
| CN106562994A (en) | Preparation method for preparing duck embryos and application of duck embryos | |
| CN112717201B (en) | Ovarian extracellular matrix scaffold and hydrogel and preparation method and application thereof | |
| CN106491652A (en) | Goose eggembryosin preparation method and application | |
| CN106562995A (en) | Preparation method for preparing swan embryos and application of swan embryos | |
| CN100402548C (en) | Preparation method of deer placenta physiologically active polypeptide | |
| CN114672456A (en) | Method for improving extracellular vesicle secretion efficiency of adipose-derived stem cells by utilizing ultrasonic stimulation and application | |
| CN106511794A (en) | Paddy rice embryo production method and application | |
| CN106620311A (en) | Preparation method and application of millet embryo extract | |
| CN108143748A (en) | A kind of dog MSC excretion body preparations and preparation method thereof | |
| CN110373381A (en) | A kind of preparation method by the efficient placenta mesenchyma stem cell of homogenizer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170419 |
|
| RJ01 | Rejection of invention patent application after publication |